Subscribe to RSS - average sales price

average sales price

OIG recommends CMS review Part B drug prices


WASHINGTON – The average sales price for 10 drug codes for the fourth quarter of 2018 exceeded the average manufacture price by 5% or more for two consecutive quarters, according to a new report from the Of

Deadline to sign infusion letter looms


WASHINGTON – The National Home Infusion Association seeks signatures for a letter that urges Congress to align the effective dates of switching to an average sales price reimbursement model for Part B infusion drugs and initiating payments for infusion services.

In brief: Two senators back bid bill, groups seek vent changes


WASHINGTON – HME stakeholders have added two co-sponsors to a bill in the Senate that would delay a second round of Medicare reimbursement cuts slated for July 1.

ASP: Budesonide takes a dive


BALTIMORE – Second quarter payments for respiratory drugs are up in most cases, with the exception of Budesonide (J7626), which decreased sharply, down nearly 73 cents per dose.

NHIA pushes back on ASP


WASHINGTON – The House of Representatives on June 17 passed a bill that included a provision that would switch payment for Part B home infusion drugs to an average sales price model—a model that is unsustainable, say infusion stakeholders.

In brief: Judge favors Lincare in whistleblower lawsuit, neb-med payments are up and down


MIAMI – A federal judge has ruled that two former Lincare employees failed to prove the provider violated Medicare telemarketing rules.

ASP: Up for brand name neb-meds


BALTIMORE – Third-quarter payments for respiratory drugs are up and down. Brand name drugs Brovana (J7605) and Perforomist (J7606) were up 16 cents and nearly 44 cents to $7.20 and $8.48 per dose, respectively.

ASP: Perforomist sees healthy jump


BALTIMORE – Fourth-quarter payments for respiratory drugs is up nearly across the board. Brand name drug Perforomist (J7606) saw the biggest jump, up nearly 90 cents, to $7.46 per dose according to the latest average sales price (ASP) figures.

OIG to CMS: Get all drug manufacturers to submit ASPs


CMS lacks complete average sales price (ASP) data for certain drugs, hindering its ability to ensure that payment amounts are accurate and reflective of manufacturer sales prices, according to a new report from the Office of Inspector General (OIG).

ASP: Brovana sees another increase


BALTIMORE – Payment increased for brand-name drug Brovana (J7605) in the third quarter of 2014 to $6.39 per dose, up 25 cents from the previous quarter, according to average sales price (ASP) figures released June 17.